Table 1 Patient background information
Age group (years) | < 65 | ≥ 65 | < 75 | ≥ 75 | ≥ 65 to < 75 | ≥ 75 to < 85 | ≥ 85 |
|---|---|---|---|---|---|---|---|
# of subjects | 280 | 1162 | 830 | 612 | 550 | 514 | 98 |
Age mean (SD) | 56.5 (7.2) | 75.5 (6.4) | 65.4 (8.0) | 80.5 (4.2) | 69.9 (2.9) | 79.1 (2.8) | 87.8 (2.8) |
Male n (%) | 206 (73.6) | 715 (61.5) | 593 (71.4) | 328 (53.6) | 387 (70.4) | 281 (54.7) | 47 (48.0) |
BMI mean (SD) | 28.8 (5.4) | 27.1 (4.7) | 28.2 (5.1) | 26.5 (4.5) | 27.8 (4.8) | 26.7 (4.6) | 25.6 (3.9) |
Hypertension n (%) | 161 (57.5) | 893 (76.9) | 568 (68.4) | 486 (79.4) | 407 (74.0) | 405 (78.8) | 81 (82.7) |
Dyslipidaemia n (%) | 74 (26.4) | 535 (46.0) | 333 (40.1) | 276 (45.1) | 259 (47.1) | 241 (46.9) | 35 (35.7) |
Diabetes mellitus n (%) | 51 (18.2) | 304 (26.2) | 188 (22.7) | 167 (27.3) | 137 (24.9) | 140 (27.2) | 27 (27.6) |
Coronary heart disease n (%) | 30 (10.7) | 272 (23.4) | 144 (17.3) | 158 (25.8) | 114 (20.7) | 135 (26.3) | 23 (23.5) |
Valvular heart disease n (%) | 33 (11.8) | 229 (19.7) | 131 (15.8) | 131 (21.4) | 98 (17.8) | 110 (21.4) | 21 (21.4) |
CrCl mean (SD) | 104.5 (37.1) | 67.0 (24.4) | 86.2 (31.6) | 57.3 (19.7) | 77.8 (24.5) | 59.7 (19.2) | 44.7 (17.9) |
CrCL ≤ 50 mL/min n (%) | 1 (0.4) | 179 (15.4) | 25 (3.0) | 155 (25.3) | 24 (4.4) | 107 (20.8) | 48 (49.0) |
CHA2DS2-VASc score mean (SD) | 1.5 (1.1) | 3.5 (1.4) | 2.4 (1.3) | 4.2 (1.3) | 2.8 (1.2) | 4.2 (1.3) | 4.4 (1.2) |
HAS-BLED score mean (SD) | 0.9 (0.9) | 2.0 (1.0) | 1.6 (1.0) | 2.1 (1.0) | 1.9 (0.9) | 2.1 (1.0) | 2.1 (1.0) |
EHRA bleeding risk-minor n (%) | 36 (12.9) | 263 (22.6) | 147 (17.7) | 152 (24.8) | 111 (20.2) | 124 (24.1) | 28 (28.6) |
EHRA bleeding risk-low n (%) | 174 (62.1) | 580 (49.9) | 457 (55.1) | 297 (48.5) | 283 (51.5) | 252 (49.0) | 45 (45.9) |
EHRA bleeding risk-high n (%) | 62 (22.1) | 289 (24.9) | 199 (24.0) | 152 (24.8) | 137 (24.9) | 129 (25.1) | 23 (23.5) |
EHRA risk unknown n (%) | 8 (2.9) | 30 (2.6) | 27 (3.3) | 11 (1.8) | 19 (3.5) | 9 (1.7) | 2 (2.0) |
30 mg daily edoxaban dose n (%) | 25 (8.9) | 341 (29.3) | 126 (15.2) | 240 (39.2) | 101 (18.4) | 173 (33.7) | 67 (68.4) |
Heparin “bridging” n (%) | 134 (9.3) | 113 (9.7) | 71 (8.6) | (10.3) | 50 (9.1) | 51 (9.9) | 12 (12.2) |